ArticleCancer management and research2019

Elevated levels of pre-treatment lactate dehydrogenase are an unfavorable predictor factor in patients with EML4-ALK rearrangement non-small cell lung cancer treated with crizotinib.

Hongge Liang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.